Structure Therapeutics Doses First Patients In Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist GSBR-1290 In Obesity
Structure Therapeutics Doses First Patients In Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist GSBR-1290 In Obesity
Structure Therapeutics對第一批患者進行了接受腹口服小分子GLP-1受體激動劑GSBR-1290的20億ACCESS臨床研究。該研究評估該藥在肥胖症中的作用。
Structure Therapeutics Doses First Patients In Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist GSBR-1290 In Obesity
Structure Therapeutics對第一批患者進行了接受腹口服小分子GLP-1受體激動劑GSBR-1290的20億ACCESS臨床研究。該研究評估該藥在肥胖症中的作用。